Patent licensing
Get paid without giving the patent away.
A licenselicensePermission from the patent owner to make, use, or sell the invention — usually in exchange for payment. Doesn't transfer ownership.Read more → is permission to use a patent in exchange for payment. The patent stays yours. Royalty rates vary wildly by industry — pharma deals run 5–25% of net sales while software is usually 1–5%. Here's the structure and the negotiation.
The three types
Exclusive, sole, and non-exclusive
Type
Exclusive license
Only the licensee can use the patent — even the patent-holder is excluded. Highest royalty rates. Effectively transfers the commercial right while keeping nominal ownership.
Type
Sole license
Licensee + patent-holder can both use it, but no one else can. Middle royalty rates. Common in research collaborations.
Type
Non-exclusive license
Licensee gets a right to use, but the patent-holder can licenselicensePermission from the patent owner to make, use, or sell the invention — usually in exchange for payment. Doesn't transfer ownership.Read more → to others too. Lowest royalty rates. SEPs (standard-essential patents) are almost always licensed non-exclusively under FRAND terms.
Typical royalty rates
What the market actually pays
Royalty rates anchor every patent licensing negotiation. Industry norms vary wildly — pharma is high because R&D is risky; software is lower because volumes are huge. Use the rate range below as a starting point, then adjust for patent strength, remaining term, and exclusivity.
| Industry | Typical royalty | Note |
|---|---|---|
| Software | 1%–5% | Of net licensee revenue. Lump-sum + small running royalty is increasingly common. |
| Pharmaceuticals | 5%–25% | Of net sales. Higher early-stage royalties offset development risk. |
| Biotech (platform tech) | 1%–10% | Plus milestone payments tied to regulatory progress. |
| Medical devices | 3%–8% | Of net selling price. Often combined with a per-unit minimum. |
| Consumer electronics | 0.5%–4% | Per-unit royalties common. SEPs (standard-essential patents) follow FRAND norms. |
| Mechanical / industrial | 2%–6% | Of net sales. Often capped at a licenselicensePermission from the patent owner to make, use, or sell the invention — usually in exchange for payment. Doesn't transfer ownership.Read more →-fee maximum. |
| Chemicals / materials | 2%–6% | Of bulk material price. Tonnage minimums often included. |
| Universities (early-stage) | 0.5%–3% | Lower running, higher equity. Often includes anti-dilution clauses. |
Ranges are market norms compiled from public IP-valuation studies. Specific deals vary widely based on patent strength, remaining term, and the licensee's alternatives.
What to negotiate
Seven terms that move the deal
- 01
Royalty base.
Net sales? Gross sales? Net of returns and chargebacks? The base often matters more than the percentage.
- 02
Royalty floor / minimum.
An annual minimum royalty protects you if the licensee under-performs. Common in exclusive licenses.
- 03
Lump-sum upfront vs running royalties.
Upfront cash de-risks the deal for the licensor but caps upside. Pure running royalties maximize upside but require trust + audit rights.
- 04
Field of use.
LicenselicensePermission from the patent owner to make, use, or sell the invention — usually in exchange for payment. Doesn't transfer ownership.Read more → only one industry vertical or product category. Lets you license the same patent to non-competing players in other fields. Universities use this constantly.
- 05
Territory.
U.S. only? North America? Worldwide ex-Japan? Geographic carve-outs preserve revenue from other regions.
- 06
Audit rights.
Without audit rights, you have no way to verify royalty reports. Standard provision: licensor can audit licensee's books annually, licensee pays if underpayment exceeds 5%.
- 07
Improvement clauses.
If the licensee invents an improvement, who owns it? Grant-back clauses keep the licensor in the loop on follow-on innovation.
Next